Merck has released provocative but limited findings from the KEYNOTE-042 trial that indicate better outcomes for first-line pembrolizumab vs standard chemotherapy in advanced non-small cell lung cancer (NSCLC).
Medscape Medical News
Original Article: Is IO Monotherapy the New Standard of Care in Advanced NSCLC?